5 Key Takeaways

• 1

  The ACNP emphasizes the need for standardization and collaboration in psychiatric biomarker development for clinical utility.

• 2

  Few psychiatric biomarkers have advanced beyond exploratory research, with trials focusing on symptoms rather than biological mechanisms.

• 3

  The proposed roadmap includes a framework for validating biomarkers through various methods, including blood assays and neuroimaging.

• 4

  Analytical validation is crucial, requiring reliable measurement of targets and established performance characteristics before clinical application.

• 5

  Near-term applications of biomarkers aim to enhance clinical trials and treatment monitoring, while long-term goals focus on precise patient subgroup identification.